Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A''-DTPA-DUPA-Pep

@article{Baur2014SynthesisRA,
  title={Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A''-DTPA-DUPA-Pep},
  author={B. Baur and C. Solbach and E. Andreolli and G. Winter and H. Machulla and S. Reske},
  journal={Pharmaceuticals},
  year={2014},
  volume={7},
  pages={517 - 529}
}
Since prostate-specific membrane antigen (PSMA) has been identified as a diagnostic target for prostate cancer, many urea-based small PSMA-targeting molecules were developed. First, the clinical application of these Ga-68 labelled compounds in positron emission tomography (PET) showed their diagnostic potential. Besides, the therapy of prostate cancer is a demanding field, and the use of radiometals with PSMA bearing ligands is a valid approach. In this work, we describe the synthesis of a new… Expand
Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer
TLDR
A pair of diagnostic/therapeutic PSMA-ligands [68Ga/177Lu]DOTAGA-ffk(Sub-KuE) possess remarkable potential for the management of prostate cancer and exhibits favourable pharmacokinetics, low unspecific uptake and high tumour accumulation in LNCaP-tumour-bearing mice. Expand
Development of a Single Vial Kit Solution for Radiolabeling of 68Ga-DKFZ-PSMA-11 and Its Performance in Prostate Cancer Patients
TLDR
The 68Ga-DKFZ-PSMA-11 kit is a robust, ready-to-use diagnostic agent in prostate cancer with high diagnostic performance. Expand
Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.
TLDR
In this preclinical evaluation (68)Ga-2 had the most advantageous characteristics for PSMA-targeted PET imaging, and demonstrated the fastest rate of clearance from all tissues in this series. Expand
Preclinical Evaluation of 86Y-Labeled Inhibitors of Prostate-Specific Membrane Antigen for Dosimetry Estimates
TLDR
PET imaging in baboons reveals that all organs have a 2-phase clearance, with the highest uptake in the kidneys at 25 min, and Dosimetry calculations indicate promise for future 90Y or other radiometals that could use a similar chelator/scaffold combination for radiopharmaceutical therapy based on the structure of 6. Expand
Preparation and Evaluation of Radiolabeled Antibody Recruiting Small Molecules That Target Prostate-Specific Membrane Antigen for Combined Radiotherapy and Immunotherapy.
TLDR
The compounds reported represent the first examples of small molecules developed specifically for combination immunotherapy and radiotherapy for prostate cancer, and showed high affinity for PSMA and the ability to bind anti-DNP antibodies. Expand
Coordination chemistry of [Y(pypa)]- and comparison immuno-PET imaging of [44Sc]Sc- and [86Y]Y-pypa-phenyl-TRC105.
TLDR
A new bifunctional H4pypa ligand is synthesized, conjugated to a monoclonal antibody, TRC105, and labeled with both radionuclides to investigate the long-term in vivo stability of each complex, showing herein that its binding cavity, in fact, favors smaller metal ions such as Sc3- and Lu3+ and further exploitation of the Sc- pypa combination is desired. Expand
Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer
TLDR
Initial safety, biodistribution, and radiation dosimetry results with [18F]DCFPyL, a second-generation fluorine-18-labeled small-molecule PSMA inhibitor, in patients with prostate cancer are presented and its accumulation is high in presumed primary and metastatic foci. Expand
RESEARCH ARTICLE Initial Evaluation of ( 18 F)DCFPyL for Prostate- Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer
TLDR
Initial safety, biodistribution, and radiation dosimetry results with [ 18 F]DCFPyL, a second-generation fluorine-18-labeled small-molecule PSMA inhibitor, in patients with prostate cancer are presented. Expand
Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals
TLDR
Evaluated tracers modified by different chelators indicate that hydrophobic entities at the chelator mediate the internalization efficacy of the PSMA inhibitors, and proves the high tumor uptake of this 68Ga-labeled PSMA-targeting compound. Expand
Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.
TLDR
The design and development of PSMA targeting motifs labeled with 68Ga for PET-CT imaging and 177Lu for therapy are described, with a focus on the broad clinical introduction of these agents. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 27 REFERENCES
PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions
TLDR
The biodistribution of the novel 68Ga-PSMA tracer and its ability to detect PC lesions was analysed in 37 patients to suggest that this novel tracer can detect PC relapses and metastases with high contrast. Expand
Comment on Afshar-Oromieh et al.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions
TLDR
In a study comprising 37 patients a discussion of 42 patients in the text needs clarification, the assumption that a prostate involved with prostate cancer and treated with local radiation therapy and androgen deprivation therapy can be regarded as a ‘normal prostate’ is not followed. Expand
Evaluation of the in vivo biodistribution of yttrium-labeled isomers of CHX-DTPA-conjugated monoclonal antibodies.
  • H. Kobayashi, C. Wu, +7 authors M. Brechbiel
  • Chemistry, Medicine
  • Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 1998
TLDR
In vivo stability and biodistribution of four isomers of 2-(p-isothiocyanatobenzyl)-cyclohexyl-diethylenetriaminepentaaceti c acid (CHX-DTPA), a recently developed backbone-substituted derivative of DTPA, are evaluated, indicating that differences in stereochemistry can greatly influence stability of radionuclide in the chelate. Expand
Radiosynthesis of a new PSMA targeting ligand ([18F]FPy-DUPA-Pep).
Due to the specificity of expression of PSMA (prostate specific membrane antigen) particularly in prostate cancer cells (e.g. LNCaP), numerous PSMA ligands have been synthesized until now. In theExpand
A cell permeable peptide analog as a potential-specific PET imaging probe for prostate cancer detection
TLDR
The goal of this work was to develop this peptide as a positron emission tomography (PET) imaging probe for specific detection of distant prostate cancer metastases and to demonstrate the PET imaging specificity of 64Cu-labled NH2GR11 for the detection of prostate cancer. Expand
68Ga-labelled DOTA-derivatised peptide ligands
TLDR
A system which allows the safe and efficient handling of 68Ge/68Ga generator eluates for labelling of DOTA-derivatised peptide ligands and built-in safety precautions have proven to be appropriate in allowing use of the method for routine clinical applications. Expand
Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs.
TLDR
It is demonstrated that the PSMA-specific ligand, 2-[3-(1, 3-dicarboxy propyl)ureido] pentanedioic acid, is capable of mediating the targeted killing of LNCaP cells with many different therapeutic warheads, suggesting that flexibility can be designed into ligand-targeted therapeutics, enabling adaptation of a single targeting ligand for the treatment of patients with different sensitivities to different chemotherapies. Expand
Yttrium-90 DOTATOC: first clinical results
TLDR
90Y-DOTATOC could be a powerful and promising new therapeutic agent for anti-cancer treatment – at least in terms of an adjuvant starting point of the disease, however, problems with toxicity have to be solved. Expand
Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.
TLDR
SPECT and PET technology has been around for decades, but its use remained limited because of the limited availability of relevant isotopes which had to be produced in nuclear reactors or particle accelerators, but the introduction of the small biomedical cyclotron, the self-contained radionuclide generator and the dedicated small animal or clinical SPECT andPET scanners to hospitals and research facilities has increased the demand for SPect and PET isotopes. Expand
Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy.
TLDR
It is found that there was no or very low response against the aromatic ring attached to DOTA, and most, if not all, of the immune response is directed against the DOTA ring structure. Expand
...
1
2
3
...